These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 23940356)

  • 1. Mutant PIK3CA accelerates HER2-driven transgenic mammary tumors and induces resistance to combinations of anti-HER2 therapies.
    Hanker AB; Pfefferle AD; Balko JM; Kuba MG; Young CD; Sánchez V; Sutton CR; Cheng H; Perou CM; Zhao JJ; Cook RS; Arteaga CL
    Proc Natl Acad Sci U S A; 2013 Aug; 110(35):14372-7. PubMed ID: 23940356
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Conditional loss of ErbB3 delays mammary gland hyperplasia induced by mutant PIK3CA without affecting mammary tumor latency, gene expression, or signaling.
    Young CD; Pfefferle AD; Owens P; Kuba MG; Rexer BN; Balko JM; Sánchez V; Cheng H; Perou CM; Zhao JJ; Cook RS; Arteaga CL
    Cancer Res; 2013 Jul; 73(13):4075-85. PubMed ID: 23633485
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibitors of STAT3, β-catenin, and IGF-1R sensitize mouse PIK3CA-mutant breast cancer to PI3K inhibitors.
    Merino VF; Cho S; Liang X; Park S; Jin K; Chen Q; Pan D; Zahnow CA; Rein AR; Sukumar S
    Mol Oncol; 2017 May; 11(5):552-566. PubMed ID: 28296140
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PI3K pathway activation results in low efficacy of both trastuzumab and lapatinib.
    Wang L; Zhang Q; Zhang J; Sun S; Guo H; Jia Z; Wang B; Shao Z; Wang Z; Hu X
    BMC Cancer; 2011 Jun; 11():248. PubMed ID: 21676217
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Luminal expression of PIK3CA mutant H1047R in the mammary gland induces heterogeneous tumors.
    Meyer DS; Brinkhaus H; Müller U; Müller M; Cardiff RD; Bentires-Alj M
    Cancer Res; 2011 Jul; 71(13):4344-51. PubMed ID: 21482677
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PI3K oncogenic mutations mediate resistance to afatinib in HER2/neu overexpressing gynecological cancers.
    Bonazzoli E; Cocco E; Lopez S; Bellone S; Zammataro L; Bianchi A; Manzano A; Yadav G; Manara P; Perrone E; Haines K; Espinal M; Dugan K; Menderes G; Altwerger G; Han C; Zeybek B; Litkouhi B; Ratner E; Silasi DA; Huang GS; Azodi M; Schwartz PE; Santin AD
    Gynecol Oncol; 2019 Apr; 153(1):158-164. PubMed ID: 30630630
    [TBL] [Abstract][Full Text] [Related]  

  • 7. H1047R phosphatidylinositol 3-kinase mutant enhances HER2-mediated transformation by heregulin production and activation of HER3.
    Chakrabarty A; Rexer BN; Wang SE; Cook RS; Engelman JA; Arteaga CL
    Oncogene; 2010 Sep; 29(37):5193-203. PubMed ID: 20581867
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PIK3CA(H1047R)- and Her2-initiated mammary tumors escape PI3K dependency by compensatory activation of MEK-ERK signaling.
    Cheng H; Liu P; Ohlson C; Xu E; Symonds L; Isabella A; Muller WJ; Lin NU; Krop IE; Roberts TM; Winer EP; Arteaga CL; Zhao JJ
    Oncogene; 2016 Jun; 35(23):2961-70. PubMed ID: 26640141
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Physiological levels of Pik3ca(H1047R) mutation in the mouse mammary gland results in ductal hyperplasia and formation of ERα-positive tumors.
    Tikoo A; Roh V; Montgomery KG; Ivetac I; Waring P; Pelzer R; Hare L; Shackleton M; Humbert P; Phillips WA
    PLoS One; 2012; 7(5):e36924. PubMed ID: 22666336
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of somatic PI3K pathway and ERBB family mutations on pathological complete response (pCR) in HER2-positive breast cancer patients who received neoadjuvant HER2-targeted therapies.
    Toomey S; Eustace AJ; Fay J; Sheehan KM; Carr A; Milewska M; Madden SF; Teiserskiene A; Kay EW; O'Donovan N; Gallagher W; Grogan L; Breathnach O; Walshe J; Kelly C; Moulton B; Kennedy MJ; Gullo G; Hill AD; Power C; Duke D; Hambly N; Crown J; Hennessy BT
    Breast Cancer Res; 2017 Jul; 19(1):87. PubMed ID: 28750640
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oncogenic PIK3CA-driven mammary tumors frequently recur via PI3K pathway-dependent and PI3K pathway-independent mechanisms.
    Liu P; Cheng H; Santiago S; Raeder M; Zhang F; Isabella A; Yang J; Semaan DJ; Chen C; Fox EA; Gray NS; Monahan J; Schlegel R; Beroukhim R; Mills GB; Zhao JJ
    Nat Med; 2011 Aug; 17(9):1116-20. PubMed ID: 21822287
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PIK3CA mutations are associated with decreased benefit to neoadjuvant human epidermal growth factor receptor 2-targeted therapies in breast cancer.
    Majewski IJ; Nuciforo P; Mittempergher L; Bosma AJ; Eidtmann H; Holmes E; Sotiriou C; Fumagalli D; Jimenez J; Aura C; Prudkin L; Díaz-Delgado MC; de la Peña L; Loi S; Ellis C; Schultz N; de Azambuja E; Harbeck N; Piccart-Gebhart M; Bernards R; Baselga J
    J Clin Oncol; 2015 Apr; 33(12):1334-9. PubMed ID: 25559818
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The H1047R PIK3CA oncogene induces a senescence-like state, pleiotropy and acute HSP90 dependency in HER2+ mammary epithelial cells.
    Chakrabarty A; Surendran S; Bhola NE; Mishra VS; Wani TH; Baghel KS; Arteaga CL; Garg R; Chowdhury G
    Carcinogenesis; 2019 Oct; 40(10):1179-1190. PubMed ID: 31219154
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association between gain-of-function mutations in PIK3CA and resistance to HER2-targeted agents in HER2-amplified breast cancer cell lines.
    Kataoka Y; Mukohara T; Shimada H; Saijo N; Hirai M; Minami H
    Ann Oncol; 2010 Feb; 21(2):255-262. PubMed ID: 19633047
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cooperation between Pik3ca and p53 mutations in mouse mammary tumor formation.
    Adams JR; Xu K; Liu JC; Agamez NM; Loch AJ; Wong RG; Wang W; Wright KL; Lane TF; Zacksenhaus E; Egan SE
    Cancer Res; 2011 Apr; 71(7):2706-17. PubMed ID: 21324922
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Decoupling of the PI3K Pathway via Mutation Necessitates Combinatorial Treatment in HER2+ Breast Cancer.
    Korkola JE; Collisson EA; Heiser M; Oates C; Bayani N; Itani S; Esch A; Thompson W; Griffith OL; Wang NJ; Kuo WL; Cooper B; Billig J; Ziyad S; Hung JL; Jakkula L; Feiler H; Lu Y; Mills GB; Spellman PT; Tomlin C; Mukherjee S; Gray JW
    PLoS One; 2015; 10(7):e0133219. PubMed ID: 26181325
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PIK3CA mutations are associated with lower rates of pathologic complete response to anti-human epidermal growth factor receptor 2 (her2) therapy in primary HER2-overexpressing breast cancer.
    Loibl S; von Minckwitz G; Schneeweiss A; Paepke S; Lehmann A; Rezai M; Zahm DM; Sinn P; Khandan F; Eidtmann H; Dohnal K; Heinrichs C; Huober J; Pfitzner B; Fasching PA; Andre F; Lindner JL; Sotiriou C; Dykgers A; Guo S; Gade S; Nekljudova V; Loi S; Untch M; Denkert C
    J Clin Oncol; 2014 Oct; 32(29):3212-20. PubMed ID: 25199759
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PI3K-p110α mediates resistance to HER2-targeted therapy in HER2+, PTEN-deficient breast cancers.
    Wang Q; Liu P; Spangle JM; Von T; Roberts TM; Lin NU; Krop IE; Winer EP; Zhao JJ
    Oncogene; 2016 Jul; 35(27):3607-12. PubMed ID: 26500061
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transcriptome- and proteome-oriented identification of dysregulated eIF4G, STAT3, and Hippo pathways altered by PIK3CA
    Cheng F; Zhao J; Hanker AB; Brewer MR; Arteaga CL; Zhao Z
    Breast Cancer Res Treat; 2016 Dec; 160(3):457-474. PubMed ID: 27771839
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low PTEN levels and PIK3CA mutations predict resistance to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2 over-expressing breast cancer.
    Rimawi MF; De Angelis C; Contreras A; Pareja F; Geyer FC; Burke KA; Herrera S; Wang T; Mayer IA; Forero A; Nanda R; Goetz MP; Chang JC; Krop IE; Wolff AC; Pavlick AC; Fuqua SAW; Gutierrez C; Hilsenbeck SG; Li MM; Weigelt B; Reis-Filho JS; Kent Osborne C; Schiff R
    Breast Cancer Res Treat; 2018 Feb; 167(3):731-740. PubMed ID: 29110152
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.